Home | Complete Product Information | Print This Page | Site Map | Contact Us |  Tell-A-Colleague
Search
blue bar
Pandemic Planning Toolkit A resource to assist your organization in preparing for pandemic influenza
Influenza Overview
Flu Pandemic Background
Preparing for a Flu Pandemic
Educational Resources
State & Local Government Resources
red arrow About TAMIFLU ® (oseltamivir phosphate)
What role could TAMIFLU play in a pandemic?
What is TAMIFLU?
How does TAMIFLU work?
What is the efficacy and safety profile on TAMIFLU?
What evidence supports TAMIFLU activity against avian flu?
What is the TAMIFLU resistance profile?
How is TAMIFLU dosed for seasonal flu?
TAMIFLU Supply and Ordering
Important Safety Information
What role could TAMIFLU play in a pandemic?

TAMIFLU to play dual role: prevention and treatment

The antiviral TAMIFLU could play two principal roles in the management of seasonal flu:
  • Prophylaxis - aimed at decreasing the likelihood of developing flu
  • Treatment - aimed at reducing the duration of flu by 1.3 days
Research has demonstrated the effectiveness of antivirals when used for both purposes. When used for treatment purposes, these drugs need to be administered within 48 hours after the onset of symptoms.22a

Tamiflu has been studied only in strains of the influenza virus that were circulating at the given time.  The magnitude of effect of Tamiflu in treating and preventing novel strains of influenza cannot predicted.

The Centers for Disease Control, along with an interagency working group with representatives from State, local and tribal public health agencies, drafted guidance on antiviral use strategies and stockpiling. The working group recommends the following strategies and settings for antiviral use:22a
  • Containing or suppressing initial pandemic outbreaks overseas and in the U.S. with treatment and post-exposure prophylaxis (PEP) among individuals identified as exposed to pandemic influenza and/or geographically targeted prophylaxis for geographic areas where exposure is thought likely to occur;


  • Reducing introduction of infection into the United States early in an influenza pandemic by post-exposure prophylaxis of exposed travelers as part of a risk-based policy at U.S. borders;


  • Treatment of persons with pandemic illness who present for care early during their illness and would benefit from such treatment;


  • Prophylaxis of critical health care workers, emergency service personnel, and workers with unique roles maintaining critical infrastructures for the duration of community outbreaks;


  • Post-exposure prophylaxis of household contacts of persons with influenza illness as a component of community mitigation

  • Post-exposure prophylaxis of workers in the health care sector with limited patient contact, of persons with compromised immune systems who are unable to be protected by vaccination, and of persons living in closed settings such as nursing homes and prisons if a pandemic outbreak occurs at that facility.

Expert recommendations for pandemic flu management 30

  1. Recent studies based on mathematical modeling suggest that antivirals could be used prophylactically near the start of a pandemic to reduce the risk that a fully transmissible virus will emerge (or at least delay its spread internationally), thus gaining time to augment vaccine supplies.

    This research has not been conducted in patients. Results are not based on a clinical study, but on mathematical modeling, which has significant limitations.

  2. The World Health Organization (WHO) recommends TAMIFLU for the prevention of pandemic influenza disease in household contacts. This recommendation is based on the effectiveness of TAMIFLU in preventing ordinary influenza in healthy and elderly patients and children ages 1 year and older. 31

Experts look to neuraminidase inhibitors for pandemic flu

  • TAMIFLU and Relenza are antivirals that belong to a drug class known as neuraminidase inhibitors. In laboratory studies, the neuraminidase inhibitors have been shown to reduce the duration of illness caused by seasonal influenza.34 The efficacy of the neuraminidase inhibitors depends on their administration within 48 hours after symptom onset. Studies are currently underway to examine the efficacy of TAMIFLU against potential pandemic strains of influenza.32
  • Another class of antiviral drugs, the M2 inhibitors amantadine and rimantadine, could potentially be used against pandemic influenza, but resistance to these drugs may develop.35
     
    -HHS Pandemic Plan

 
For more information about Tamiflu resistance, please see What is the TAMIFLU resistance profile?

 
FOOTNOTE
22a Centers for Disease Control (CDC), Proposed Guidance on
Antivirals Drug Use Strategies during an Influenza Pandemic,
November 8, 2007; Available at: http://www.businessgrouphealth.org/benefitstopics/topics/avianfludocs/110607_
antiviraldrugusestrategiesfedguidance.pdf
22. US Dept of Health and Human Services. Pandemic planning update: a report from Secretary Michael O. Leavitt (2006). Available at: http://www.pandemicflu.gov/plan/pdf/panflu20060313.pdf. Accessed April 13, 2006.
30. US Dept of Health and Human Services. Centers for Disease Control and Prevention Web site. Interim Guidance for Protection of Persons Involved in U.S. Avian Influenza Outbreak Disease Control and Eradication Activities. Available at: http://www.cdc.gov/flu/avian/professional/protect-guid.htm. Accessed April 24, 2006
31. World Health Organization Web site. Advice on use of oseltamivir. Available at: http://www.who.int/csr/disease/avian_influenza/guidelines/-
useofoseltamivir2006_03_17A.pdf. Accessed May 16, 2006.
32. World Health Organization Website. Antiviral drugs: their role during a pandemic. November 2005. Available at: http://www.who.int/CSR/disease/avian_influenza/antivirals2005_11_3/en/.
33. Data on file. NDC #. Hoffmann-La Roche, Nutley NJ.
34. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neauraminidise inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000;28: 1016-1024.
35. US Dept of Health and Human Services. Supplement 7 Antiviral Drug Distribution and Use. Available at: http://www.hhs.gov/ pandemicflu/plan/sup7.html#5. Accessed April 19, 2006.
Guidelines
Bi-Weekly Pandemic News Monitor Reports Bi-Weekly Pandemic News Monitor Reports
Contact Us Contact Us

 
spacer.gif
Home | Complete Product Information  |    Tell-A-Colleague  | Site Map  |  Contact Us
spacer.gif
Influenza Overview  |  Flu Pandemic Background  |  Preparing for a Flu Pandemic
About TAMIFLU ® (oseltamivir phosphate)  |  TAMIFLU Supply and Ordering  |  Educational Resources
State & Local Government Resources  |  Important Safety Information
spacer.gif
Legal Statement   |  Privacy Statement |  Unsubscribe

 
IMPORTANT SAFETY INFORMATION


TAMIFLU has not been shown to be effective against any illness other than that caused by influenza types A and B. Efficacy of treatment in patients with chronic cardiac and/or respiratory disease has not been established. No difference in the incidence of complications was seen between the treatment and placebo groups in this population. No information is available regarding treatment of influenza in patients at imminent risk of requiring hospitalization. Efficacy of TAMIFLU has not been established in immunocompromised patients.

Safety and efficacy of repeated courses of TAMIFLU for treatment or prevention have not been studied. In postmarketing experience, rare cases of anaphylaxis and serious skin reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, have been reported.

There have been postmarketing reports (mostly from Japan) of self-injury and delirium with the use of TAMIFLU in patients with influenza. The reports were primarily among children. The relative contribution of the drug to these events is not known. Patients with influenza should be closely monitored for signs of abnormal behavior throughout the treatment period. In treatment studies in adult patients, the most frequently reported adverse events (incidence ≥ 1%) were nausea and vomiting. Other events reported numerically more frequently in patients taking TAMIFLU compared with placebo were bronchitis, insomnia and vertigo. In treatment studies in patients 1 to 12 years old, the most frequently reported adverse event (incidence ≥ 1%) was vomiting (15%). Other events reported more frequently in patients taking TAMIFLU compared with placebo included abdominal pain (5% vs 4%), nosebleed (3% vs 3%), ear disorder (2% vs 1%) and pinkeye (1% vs < 1%).

In prophylaxis studies in adult patients, adverse events were similar to those seen in the treatment studies. Events reported more frequently in patients taking TAMIFLU compared with placebo (incidence ≥ 1%) were nausea (7% vs 3%), vomiting (2% vs 1%), diarrhea (3% vs 2%), abdominal pain (2% vs 1%), dizziness (1% vs 1%), headache (18% vs 18%) and insomnia (1% vs 1%). In a household prevention trial that included patients 1 to 12 years old, adverse events were similar to those observed in pediatric treatment studies, with GI events being the most common.

The concurrent use of TAMIFLU and live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, due to the possibility for interference between these products, LAIV should not be given within 2 weeks before or 48 hours after taking TAMIFLU, unless it is deemed appropriate by your doctor. Trivalent inactivated influenza vaccine can be administered at any time relative to use of TAMIFLU.

 

Roche THIS SITE INTENDED FOR U.S. AUDIENCES ONLY
Copyright © 2006-2008 Hoffmann-La Roche Inc. All rights reserved. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Statement.